

# John M Lachin

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2316927/john-m-lachin-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

255  
papers

50,962  
citations

81  
h-index

225  
g-index

278  
ext. papers

58,800  
ext. citations

10.4  
avg, IF

7.36  
L-index

#	Paper	IF	Citations
255	Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 393-403	59.2	13212
254	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2117-28	59.2	6064
253	Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 2643-53	59.2	3690
252	Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 2427-43	59.2	2332
251	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 323-34	59.2	1956
250	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 232-42	59.2	1739
249	Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 381-9	59.2	1234
248	Effect of weight loss with lifestyle intervention on risk of diabetes. <i>Diabetes Care</i> , <b>2006</b> , 29, 2102-7	14.6	851
247	Introduction to sample size determination and power analysis for clinical trials. <i>Contemporary Clinical Trials</i> , <b>1981</b> , 2, 93-113		737
246	Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2143-52	59.2	717
245	Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 2294-303	59.2	656
244	Effects of insulin in relatives of patients with type 1 diabetes mellitus. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 1685-91	59.2	655
243	Statistical considerations in the intent-to-treat principle. <i>Contemporary Clinical Trials</i> , <b>2000</b> , 21, 167-89		466
242	Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). <i>Diabetes Care</i> , <b>2008</b> , 31, 845-51	14.6	431
241	Achieving weight and activity goals among diabetes prevention program lifestyle participants. <i>Obesity</i> , <b>2004</b> , 12, 1426-34		412
240	Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. <i>Diabetes Care</i> , <b>2007</b> , 30, 2453-7	14.6	394
239	Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 2366-76	59.2	390

238	A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 1373-9	59.2	381
237	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 356-363	14.6	365
236	Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. <i>Diabetes</i> , <b>2008</b> , 57, 995-1001	0.9	340
235	Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 45-53	27.4	290
234	Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. <i>Diabetes Care</i> , <b>2003</b> , 26, 36-47	14.6	272
233	Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification. <i>Biometrics</i> , <b>1986</b> , 42, 507	1.8	264
232	A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 1564-9	59.2	260
231	Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Diabetes Care</i> , <b>2010</b> , 33, 1090-6	14.6	259
230	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , <b>2018</b> , 137, 119-129	16.7	252
229	Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. <i>JAMA Ophthalmology</i> , <b>2008</b> , 126, 1707-15		248
228	Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. <i>Archives of Internal Medicine</i> , <b>2011</b> , 171, 412-20		238
227	Properties of the urn randomization in clinical trials. <i>Contemporary Clinical Trials</i> , <b>1988</b> , 9, 345-64		237
226	Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). <i>Circulation</i> , <b>2009</b> , 119, 2886-93	16.7	229
225	Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. <i>Diabetes</i> , <b>2012</b> , 61, 2066-73	0.9	216
224	Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. <i>Diabetes Care</i> , <b>2010</b> , 33, 1536-43	14.6	207
223	Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. <i>Diabetes Care</i> , <b>2008</b> , 31, 1966-71	14.6	203
222	Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. <i>Diabetes</i> , <b>2015</b> , 64, 631-42	0.9	202
221	The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. <i>Diabetes</i> , <b>2006</b> , 55, 3556-65	0.9	202

220	Properties of permuted-block randomization in clinical trials. <i>Contemporary Clinical Trials</i> , <b>1988</b> , 9, 327-44		198
219	Randomization in clinical trials: conclusions and recommendations. <i>Contemporary Clinical Trials</i> , <b>1988</b> , 9, 365-74		190
218	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimpiride in Type 2 Diabetes (CAROLINA <sup>2</sup> ). <i>Diabetes and Vascular Disease Research</i> , <b>2015</b> , 12, 164-74	3.3	182
217	A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. <i>Diabetes Care</i> , <b>2002</b> , 25, 1737-43	14.6	180
216	Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). <i>Diabetes Care</i> , <b>2013</b> , 36, 2254-61	14.6	173
215	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME <sup>2</sup> trial. <i>European Heart Journal</i> , <b>2018</b> , 39, 363-370	9.7	171
214	The role of measurement reliability in clinical trials. <i>Clinical Trials</i> , <b>2004</b> , 1, 553-66	2.2	171
213	Effects of rosiglitazone, glyburide, and metformin on $\beta$ cell function and insulin sensitivity in ADOPT. <i>Diabetes</i> , <b>2011</b> , 60, 1552-60	0.9	164
212	Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. <i>Diabetes</i> , <b>2013</b> , 62, 3976-86	0.9	162
211	Natural history and course of acquired lactic acidosis in adults. DCA-Lactic Acidosis Study Group. <i>American Journal of Medicine</i> , <b>1994</b> , 97, 47-54	2.4	161
210	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 126-35	16.2	161
209	Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. <i>Diabetes</i> , <b>2014</b> , 63, 1748-62	0.9	159
208	Statistical properties of randomization in clinical trials. <i>Contemporary Clinical Trials</i> , <b>1988</b> , 9, 289-311		157
207	A review of methods for futility stopping based on conditional power. <i>Statistics in Medicine</i> , <b>2005</b> , 24, 2747-64	2.3	155
206	Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. <i>Diabetes</i> , <b>2006</b> , 55, 2357-64	0.9	154
205	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME <sup>2</sup> ). <i>Cardiovascular Diabetology</i> , <b>2014</b> , 13, 102	8.7	153
204	Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. <i>Diabetes Care</i> , <b>2014</b> , 37, 39-43	14.6	140
203	Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. <i>Diabetes</i> , <b>2014</b> , 63, 282-90	0.9	138

202	Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 134-42	5.6	138
201	Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. <i>Diabetes</i> , <b>2014</b> , 63, 739-48	0.9	137
200	Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E3002-11	11.5	132
199	The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. <i>Pediatric Diabetes</i> , <b>2009</b> , 10, 97-104	3.6	131
198	Worst-rank score analysis with informatively missing observations in clinical trials. <i>Contemporary Clinical Trials</i> , <b>1999</b> , 20, 408-22		126
197	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1094	59.2	125
196	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. <i>Diabetes and Vascular Disease Research</i> , <b>2013</b> , 10, 289-301	3.3	119
195	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 128-139	18.1	119
194	Fallacies of last observation carried forward analyses. <i>Clinical Trials</i> , <b>2016</b> , 13, 161-8	2.2	117
193	Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. <i>Diabetes Care</i> , <b>2010</b> , 33, 826-32	14.6	114
192	Properties of simple randomization in clinical trials. <i>Contemporary Clinical Trials</i> , <b>1988</b> , 9, 312-26		114
191	Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. <i>American Journal of Clinical Nutrition</i> , <b>2009</b> , 89, 518-24	7	103
190	Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> , <b>2017</b> , 40, 777-783	14.6	102
189	Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. <i>Diabetes</i> , <b>2011</b> , 60, 607-13	0.9	101
188	Pretreatment Biliary Lipid Composition in White Patients with Radiolucent Gallstones in the National Cooperative Gallstone Study. <i>Gastroenterology</i> , <b>1982</b> , 83, 738-752	13.3	97
187	Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. <i>Statistics in Medicine</i> , <b>1992</b> , 11, 1151-70	2.3	95
186	Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data. <i>Journal of the American Statistical Association</i> , <b>1988</b> , 83, 339-347	2.8	94
185	Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. <i>Diabetes</i> , <b>2015</b> , 64, 266-78	0.9	90

184	DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. <i>Current Diabetes Reports</i> , <b>2010</b> , 10, 276-82	5.6	89
183	Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. <i>Diabetes Care</i> , <b>2018</b> , 41, 1696-1706	14.6	89
182	A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. <i>Diabetes Care</i> , <b>2008</b> , 31, 528-33	14.6	88
181	Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> , <b>2017</b> , 40, 1010-1016	14.6	86
180	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , <b>2017</b> , 48, 1218-1225	6.7	86
179	Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. <i>Diabetes</i> , <b>2008</b> , 57, 218-28	0.9	83
178	A genome-wide association study identifies a novel major locus for glycemic control in type 1 diabetes, as measured by both A1C and glucose. <i>Diabetes</i> , <b>2010</b> , 59, 539-49	0.9	81
177	Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. <i>Archives of Internal Medicine</i> , <b>2008</b> , 168, 1867-73		81
176	Type 1 Diabetes TrialNet--an international collaborative clinical trials network. <i>Annals of the New York Academy of Sciences</i> , <b>2008</b> , 1150, 14-24	6.5	81
175	National Cooperative Gallstone Study. <i>Gastroenterology</i> , <b>1982</b> , 82, 638-646	13.3	79
174	Effect of rituximab on human in vivo antibody immune responses. <i>Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 128, 1295-1302.e5	11.5	76
173	Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. <i>Diabetes</i> , <b>2009</b> , 58, 2588-95	0.9	76
172	The use of response-adaptive designs in clinical trials. <i>Contemporary Clinical Trials</i> , <b>1993</b> , 14, 471-84		75
171	Impact of Insulin and Metformin Versus Metformin Alone on $\beta$ Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , <b>2018</b> , 41, 1717-1725	14.6	74
170	Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1507-1516	59.2	73
169	Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. <i>Diabetes</i> , <b>2011</b> , 60, 582-9	0.9	70
168	Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2016</b> , 11, 1969-1977	6.9	69
167	Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. <i>Diabetes</i> , <b>2007</b> , 56, 1153-9	0.9	66



166	Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , <b>2019</b> , 42, 875-882	14.6	63
165	Intensive diabetes therapy and ocular surgery in type 1 diabetes. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1722-33	59.2	63
164	Renal outcomes in patients with type 1 diabetes and macroalbuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 2342-50	12.7	63
163	Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. <i>Journal of Urology</i> , <b>2011</b> , 185, 1828-34	2.5	62
162	Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. <i>Circulation</i> , <b>2011</b> , 124, 1737-46	16.7	62
161	Parametric survival models for interval-censored data with time-dependent covariates. <i>Biostatistics</i> , <b>2006</b> , 7, 599-614	3.7	61
160	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. <i>Diabetes Care</i> , <b>2018</b> , 41, 1887-1894	14.6	59
159	Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2011</b> , 6, 1032-40	6.9	58
158	The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. <i>Diabetes Care</i> , <b>2007</b> , 30, 2107-12	14.6	57
157	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves $\beta$ Cell Function and Improves HbA in New-Onset Type 1 Diabetes. <i>Diabetes Care</i> , <b>2018</b> , 41, 1917-1925	14.6	56
156	Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. <i>Biostatistics</i> , <b>2016</b> , 17, 178-87	3.7	53
155	Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. <i>Journal of Immunology</i> , <b>2011</b> , 187, 1998-2005	5.3	51
154	Implementation of Group Sequential Logrank Tests in a Maximum Duration Trial. <i>Biometrics</i> , <b>1990</b> , 46, 759	1.8	50
153	The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. <i>Diabetes</i> , <b>2007</b> , 56, 1913-21	0.9	47
152	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , <b>2017</b> , 40, 1763-1770	14.6	46
151	Sample Size Determinations for $r \times c$ Comparative Trials. <i>Biometrics</i> , <b>1977</b> , 33, 315	1.8	46
150	The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study. <i>Diabetologia</i> , <b>2017</b> , 60, 2084-2091	10.3	45
149	Circulating vitamin D metabolites and kidney disease in type 1 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 4780-8	5.6	45

148	Power and sample size evaluation for the McNemar test with application to matched case-control studies. <i>Statistics in Medicine</i> , <b>1992</b> , 11, 1239-51	2.3	45
147	Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. <i>Diabetes</i> , <b>2020</b> , 69, 1000-1010	0.9	44
146	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , <b>2018</b> , 41, 596-603	14.6	44
145	Determining stability of stored samples retrospectively: the validation of glycated albumin. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 286-90	5.5	44
144	Depression as a symptom of alcoholism: search for a phenomenon. <i>Journal of Abnormal Psychology</i> , <b>1968</b> , 73, 195-7	7	43
143	A prospective morphologic evaluation of hepatic toxicity of chenodeoxycholic acid in patients with cholelithiasis: the National Cooperative Gallstone Study. <i>Hepatology</i> , <b>1982</b> , 2, 187-201	11.2	42
142	The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2013</b> , 27, 141-9	3.2	41
141	Interim analyses with repeated measurements in a sequential clinical trial. <i>Biometrika</i> , <b>1990</b> , 77, 359-364	2	40
140	Pancreatic Safety of Sitagliptin in the TECOS Study. <i>Diabetes Care</i> , <b>2017</b> , 40, 164-170	14.6	39
139	Risk Factors for Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , <b>2019</b> , 42, 883-890	14.6	37
138	Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. <i>Atherosclerosis</i> , <b>2011</b> , 214, 462-7	3.1	36
137	Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2010</b> , 5, 1235-42	6.9	36
136	Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. <i>Cardiovascular Diabetology</i> , <b>2015</b> , 14, 118	8.7	35
135	Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). <i>Diabetes Care</i> , <b>2010</b> , 33, 177-83	14.6	34
134	Sample size evaluation for a multiply matched case-control study using the score test from a conditional logistic (discrete Cox PH) regression model. <i>Statistics in Medicine</i> , <b>2008</b> , 27, 2509-23	2.3	34
133	High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , <b>2012</b> , 27, 1416-23	4.3	33
132	Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes. <i>PLoS ONE</i> , <b>2011</b> , 6, e26471	3.7	33
131	Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). <i>Diabetes</i> , <b>2015</b> , 64, 989-98	0.9	32



130	Assessment of stratum-covariate interactions in Cox's proportional hazards regression model. <i>Statistics in Medicine</i> , <b>1986</b> , 5, 73-83	2.3	32
129	Longitudinal changes in estimated and measured GFR in type 1 diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 810-8	12.7	31
128	Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC. <i>Diabetes</i> , <b>2013</b> , 62, 3561-9	0.9	31
127	Ultrastructural Evidence of Intrahepatic Cholestasis Before and After Chenodeoxycholic Acid Therapy in Patients with Cholelithiasis: The National Cooperative Gallstone Study. <i>Hepatology</i> , <b>2007</b> , 3, 209-220	11.2	31
126	Lack of Durable Improvements in $\beta$ Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , <b>2019</b> , 42, 1742-1751	14.6	30
125	Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. <i>Diabetes</i> , <b>2013</b> , 62, 3218-23	0.9	30
124	Association of Cardiovascular Risk Factors and Myocardial Fibrosis With Early Cardiac Dysfunction in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes Care</i> , <b>2017</b> , 40, 405-411	14.6	28
123	Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 364-367	15.1	28
122	Group Sequential Distribution-Free Methods for the Analysis of Multivariate Observations. <i>Biometrics</i> , <b>1992</b> , 48, 1033	1.8	28
121	On stepwise discriminant analyses applied to physiologic data. <i>Psychophysiology</i> , <b>1974</b> , 11, 703-9	4.1	28
120	Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , <b>2019</b> , 42, 1284-1289	14.6	27
119	Circulating vitamin D metabolites and subclinical atherosclerosis in type 1 diabetes. <i>Diabetes Care</i> , <b>2013</b> , 36, 2423-9	14.6	27
118	Link-Based Models for Survival Data with Interval and Continuous Time Censoring. <i>Biometrics</i> , <b>1997</b> , 53, 1199	1.8	27
117	. <i>Wiley Series in Probability and Statistics</i> , <b>2010</b> ,	1.3	27
116	Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data		26
115	Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 867-874	14.6	26
114	The Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes: The DCCT/EDIC Trials. <i>JACC: Cardiovascular Imaging</i> , <b>2019</b> , 12, 1341-1349	8.4	24
113	Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> , <b>2019</b> , 42, 657-664	14.6	24

112	Applications of the Wei-Lachin multivariate one-sided test for multiple outcomes on possibly different scales. <i>PLoS ONE</i> , <b>2014</b> , 9, e108784	3.7	22
111	Termination of a clinical trial with no treatment group difference: the Lupus Nephritis Collaborative Study. <i>Contemporary Clinical Trials</i> , <b>1992</b> , 13, 62-79		22
110	Use of spending functions for occasional or continuous monitoring of data in clinical trials. <i>Statistics in Medicine</i> , <b>1993</b> , 12, 2219-31	2.3	22
109	Application of the Wei-Lachin multivariate one-directional test to multiple event-time outcomes. <i>Clinical Trials</i> , <b>2015</b> , 12, 627-33	2.2	21
108	Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit. <i>Clinical Trials</i> , <b>2009</b> , 6, 565-73	2.2	20
107	The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2015</b> , 29, 108-14	3.2	19
106	Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2019</b> , 14, 854-861	6.9	18
105	Aortic distensibility in type 1 diabetes. <i>Diabetes Care</i> , <b>2013</b> , 36, 2380-7	14.6	18
104	Point: Intensive glycemic control and mortality in ACCORD--a chance finding?. <i>Diabetes Care</i> , <b>2010</b> , 33, 2719-21	14.6	17
103	DNA methylation mediates development of HbA1c-associated complications in type 1 diabetes. <i>Nature Metabolism</i> , <b>2020</b> , 2, 744-762	14.6	17
102	What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?. <i>Journal of Diabetes and Its Complications</i> , <b>2018</b> , 32, 911-915	3.2	16
101	Estimators and Tests in the Analysis of Multiple Nonindependent 2 X 2 Tables with Partially Missing Observations. <i>Biometrics</i> , <b>1988</b> , 44, 513	1.8	16
100	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. <i>Circulation</i> , <b>2018</b> , 138, 1599-1601	16.7	16
99	Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes. <i>Cardiovascular Diabetology</i> , <b>2016</b> , 15, 30	8.7	15
98	Sequential Monitoring of Survival Data with the Wilcoxon Statistic. <i>Biometrics</i> , <b>1995</b> , 51, 1175	1.8	15
97	Residual $\chi^2$ function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	15
96	Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. <i>Diabetes Care</i> , <b>2018</b> , 41, 2495-2501	14.6	15
95	Pilot genome-wide association search identifies potential loci for risk of erectile dysfunction in type 1 diabetes using the DCCT/EDIC study cohort. <i>Journal of Urology</i> , <b>2012</b> , 188, 514-20	2.5	14

94	Power and sample size evaluation for the Cochran-Mantel-Haenszel mean score (Wilcoxon rank sum) test and the Cochran-Armitage test for trend. <i>Statistics in Medicine</i> , <b>2011</b> , 30, 3057-66	2.3	14
93	External monitoring of a data coordinating center: experience of the National Cooperative Gallstone Study. <i>Contemporary Clinical Trials</i> , <b>1987</b> , 8, 1-11		14
92	Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 436-445	18.1	14
91	Group sequential monitoring of distribution-free analyses of repeated measures. <i>Statistics in Medicine</i> , <b>1997</b> , 16, 653-68	2.3	13
90	Progression of Electrocardiographic Abnormalities in Type 1 Diabetes During 16 Years of Follow-up: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5, e002882	6	13
89	Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Diabetes Care</i> , <b>2017</b> , 40, 793-799	14.6	12
88	Over-ruling a group sequential boundary—a stopping rule versus a guideline. <i>Statistics in Medicine</i> , <b>2003</b> , 22, 3347-55	2.3	12
87	Significance of Epicardial and Intrathoracic Adipose Tissue Volume among Type 1 Diabetes Patients in the DCCT/EDIC: A Pilot Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0159958	3.7	12
86	Haptoglobin 2-2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). <i>Journal of Diabetes and Its Complications</i> , <b>2016</b> , 30, 1577-1584	3.2	11
85	A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. <i>Pediatric Diabetes</i> , <b>2011</b> , 12, 85-90	3.6	11
84	Properties of randomization in clinical trials: Foreword. <i>Contemporary Clinical Trials</i> , <b>1988</b> , 9, 287-288		11
83	Central laboratory quality control in the National Cooperative Gallstone Study. <i>Contemporary Clinical Trials</i> , <b>1983</b> , 4, 101-23		11
82	Immune Complexes and the Risk of CVD in Type 1 Diabetes. <i>Diabetes</i> , <b>2019</b> , 68, 1853-1860	0.9	10
81	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin. <i>Hypertension</i> , <b>2017</b> , 70, 907-914	8.5	10
80	Operating characteristics of sample size re-estimation with futility stopping based on conditional power. <i>Statistics in Medicine</i> , <b>2006</b> , 25, 3348-65	2.3	10
79	A flexible stochastic curtailing procedure for the log-rank test. <i>Contemporary Clinical Trials</i> , <b>2000</b> , 21, 428-39		10
78	Nonparametric Statistical Analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 2080-2081		9
77	Application of robust estimating equations to the analysis of quantitative longitudinal data. <i>Statistics in Medicine</i> , <b>2001</b> , 20, 3411-28	2.3	9

76	On a Stepwise Procedure for Two Population Bayes Decision Rules Using Discrete Variables. <i>Biometrics</i> , <b>1973</b> , 29, 551	1.8	9
75	Validity of self-report in type 1 diabetic subjects for laser treatment of retinopathy. <i>Ophthalmology</i> , <b>2013</b> , 120, 2580-2586	7.3	8
74	Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata. <i>Statistics in Medicine</i> , <b>2013</b> , 32, 4413-25	2.3	8
73	Conflicts of interest in data monitoring of industry versus publicly financed clinical trials. <i>Statistics in Medicine</i> , <b>2004</b> , 23, 1519-21	2.3	8
72	Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes: response to McCarter et al. <i>Diabetes Care</i> , <b>2005</b> , 28, 233; author reply 234-5	14.6	8
71	The National Cooperative Gallstone Study and current management of cholesterol cholelithiasis—two views. <i>Gastroenterology</i> , <b>1983</b> , 84, 644-648	13.3	8
70	Sequential Clinical Trials for Normal Variates Using Interval Composite Hypotheses. <i>Biometrics</i> , <b>1981</b> , 37, 87	1.8	8
69	An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 2478-2484	14.6	8
68	OGTT Glucose Response Curves, Insulin Sensitivity, and $\beta$ Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve $\beta$ Cell Function. <i>Diabetes Care</i> , <b>2021</b> , 44, 817-825	14.6	7
67	Maximum information designs. <i>Clinical Trials</i> , <b>2005</b> , 2, 453-64	2.2	6
66	Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC). <i>Diabetes Care</i> , <b>2021</b> ,	14.6	6
65	Association of Habitual Daily Physical Activity With Glucose Tolerance and $\beta$ Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study. <i>Diabetes Care</i> , <b>2019</b> , 42, 1521-1529	14.6	5
64	Power of the Mantel-Haenszel and other tests for discrete or grouped time-to-event data under a chained binomial model. <i>Statistics in Medicine</i> , <b>2013</b> , 32, 220-9	2.3	5
63	Biomarkers of tubulointerstitial damage and function in type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , <b>2017</b> , 5, e000461	4.5	5
62	Relation between carotid intima-media thickness and left ventricular mass in type 1 diabetes mellitus (from the Epidemiology of Diabetes Interventions and Complications [EDIC] Study). <i>American Journal of Cardiology</i> , <b>2012</b> , 110, 1534-40	3	5
61	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	5
60	Optimal screening schedules for disease progression with application to diabetic retinopathy. <i>Biostatistics</i> , <b>2018</b> , 19, 1-13	3.7	5
59	The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes. <i>Diabetes Care</i> , <b>2021</b> ,	14.6	5

58	The Society for Clinical Trials supports United States legislation mandating trials registration. Position paper. <i>Clinical Trials</i> , <b>2004</b> , 1, 417-20	2.2	4
57	Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes. <i>Diabetes Care</i> , <b>2021</b> , 44, 1499-1505	14.6	4
56	Stratified-adjusted versus unstratified assessment of sample size and power for analyses of proportions. <i>Cancer Treatment and Research</i> , <b>1995</b> , 75, 203-23	3.5	4
55	Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. <i>Diabetes</i> 2020;69:291-299. <i>Diabetes</i> , <b>2020</b> , 69, e7-e8	0.9	3
54	Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. <i>Diabetes Care</i> 2017;40:655-662. <i>Diabetes Care</i> , <b>2018</b> , 41, e64	14.6	3
53	Major issues in the organization and implementation of the National Cooperative Gallstone Study (NCGS). <i>Contemporary Clinical Trials</i> , <b>1984</b> , 5, 1-12		3
52	Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently-diagnosed type 2 diabetes. <i>Pediatric Diabetes</i> , <b>2020</b> , 21, 1437-1446	3.6	3
51	Mediation of the association of smoking and microvascular complications by glycemic control in type 1 diabetes. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210367	3.7	3
50	Association of Baseline Characteristics With Insulin Sensitivity and $\beta$ Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. <i>Diabetes Care</i> , <b>2021</b> , 44, 340-349	14.6	3
49	Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients. <i>Journal of Diabetes Investigation</i> , <b>2021</b> ,	3.9	3
48	Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> 2017;40:777-783. <i>Diabetes Care</i> , <b>2017</b> , 40, e165-e166	14.6	2
47	Models to Assess the Association of a Semiquantitative Exposure With Outcomes. <i>American Journal of Epidemiology</i> , <b>2020</b> , 189, 1573-1582	3.8	2
46	Properties of composite time to first event versus joint marginal analyses of multiple outcomes. <i>Statistics in Medicine</i> , <b>2018</b> , 37, 3918-3930	2.3	2
45	Nonparametric test of stochastic ordering for multiple longitudinal measures. <i>Journal of Biopharmaceutical Statistics</i> , <b>1995</b> , 5, 235-43	1.3	2
44	Distribution-Free Marginal Analysis of Repeated Measures. <i>Drug Information Journal</i> , <b>1996</b> , 30, 1017-1028		2
43	Effects of dose relative to body weight in the National Cooperative Gallstone Study: a fixed-dose trial. <i>Contemporary Clinical Trials</i> , <b>1983</b> , 4, 125-31		2
42	Phasic heart rate responses: different patterns in black and in white newborns. <i>Psychosomatic Medicine</i> , <b>1975</b> , 37, 326-32	3.7	2
41	Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC.. <i>BMJ Open Diabetes Research and Care</i> , <b>2022</b> , 10,	4.5	2

40	Association of glycemia with insulin sensitivity and $\beta$ cell function in adults with early type 2 diabetes on metformin alone. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 107912	3.2	2
39	Hyperglucagonemia Does Not Explain the $\beta$ Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. <i>Diabetes Care</i> , <b>2021</b> , 44, 1961-1969	14.6	2
38	Refractive Error and Retinopathy Outcomes in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Ophthalmology</i> , <b>2021</b> , 128, 554-560	7.3	2
37	Moderation of the effect of glycemia on the risk of cardiovascular disease in type 1 diabetes: The DCCT/EDIC study. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 171, 108591	7.4	2
36	Refining Measurement of Hemoglobin A. <i>Clinical Chemistry</i> , <b>2017</b> , 63, 1433-1435	5.5	1
35	RISK FACTORS FOR HEARING IMPAIRMENT IN TYPE 1 DIABETES. <i>Endocrine Practice</i> , <b>2019</b> , 25, 1243-1254	3.2	1
34	Data sharing is desirable, but benefits should not be exaggerated. <i>BMJ, The</i> , <b>2015</b> , 351, h5508	5.9	1
33	Methods for a longitudinal quantitative outcome with a multivariate Gaussian distribution multi-dimensionally censored by therapeutic intervention. <i>Statistics in Medicine</i> , <b>2014</b> , 33, 1288-306	2.3	1
32	National Cooperative Gallstone Study <b>2008</b> , 1		1
31	A composite design for transition from a preliminary to a full-scale study. <i>Statistics in Medicine</i> , <b>2007</b> , 26, 5014-32	2.3	1
30	Group sequential large sample T2-like chi2 tests for multivariate observations. <i>Statistics in Medicine</i> , <b>2003</b> , 22, 3357-68	2.3	1
29	Corrections for Bias in Maximum Likelihood Parameter Estimates Due to Nuisance Parameters. <i>Communications in Statistics Part B: Simulation and Computation</i> , <b>2003</b> , 32, 619-639	0.6	1
28	Martingales without tears. <i>Lifetime Data Analysis</i> , <b>1995</b> , 1, 361-75	1.3	1
27	Remembrances of Max Halperin. <i>Statistics in Medicine</i> , <b>1990</b> , 9, 863-70	2.3	1
26	Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies. <i>PLoS ONE</i> , <b>2021</b> , 16, e0257154	3.7	1
25	Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , <b>2021</b> , 44, 1309-1316	16.6	1
24	Coronary Artery Disease Events and Carotid Intima-Media Thickness in Type 1 Diabetes in the DCCT/EDIC Cohort. <i>Journal of the American Heart Association</i> , <b>2021</b> , e022922	6	1
23	Closed testing using surrogate hypotheses with restricted alternatives. <i>PLoS ONE</i> , <b>2019</b> , 14, e0219520	3.7	0



22	Severe hypoglycaemia in Diabetes Control and Complications Trial. <i>Lancet, The</i> , <b>1994</b> , 343, 1097-8	4.0	o
21	Identifying change points in a covariate effect on time-to-event analysis with reduced isotonic regression. <i>PLoS ONE</i> , <b>2014</b> , 9, e113948	3.7	o
20	Closed testing of each group versus the others combined in a multiple group analysis. <i>Clinical Trials</i> , <b>2020</b> , 17, 77-86	2.2	o
19	Worst-Rank Score Methods-A Nonparametric Approach to Informatively Missing Data. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 1670-1671	27.4	o
18	Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. <i>Diabetes</i> , <b>2020</b> , 69, 2440-2445	0.9	o
17	Probabilistic measures of cost-effectiveness. <i>Statistics in Medicine</i> , <b>2016</b> , 35, 3976-86	2.3	o
16	University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (afternoon panel session). <i>Clinical Trials</i> , <b>2018</b> , 15, 366-385	2.2	
15	Intention-to-Treat: Overview <b>2018</b> , 1-10		
14	Intention-to-Treat Analysis <b>2014</b> , 313-322		
13	Reminiscences of Jerry Cornfield. <i>Clinical Trials</i> , <b>2013</b> , 10, 337-9	2.2	
12	Intention-to-Treat Analysis <b>2008</b> , 1		
11	Permutation tests following restricted randomization procedures. <i>Contemporary Clinical Trials</i> , <b>1990</b> , 11, 150-152		
10	Early Termination of the Diabetes Control and Complications Trial <b>2006</b> , 93-108		
9	Randomization as a Basis for Inference. <i>Wiley Series in Probability and Statistics</i> , 97-132	1.3	
8	Stratification. <i>Wiley Series in Probability and Statistics</i> , 133-146	1.3	
7	Issues in the Design of Clinical Trials. <i>Wiley Series in Probability and Statistics</i> , 15-36	1.3	
6	Response-Adaptive Randomization in Practice. <i>Wiley Series in Probability and Statistics</i> , 231-242	1.3	
5	Randomization for Balancing Treatment Assignments. <i>Wiley Series in Probability and Statistics</i> , 37-66	1.3	

4	Restricted Randomization in Practice. <i>Wiley Series in Probability and Statistics</i> ,147-168	1.3
3	The minimum intensity of a mixed exposure that increases the risk of an outcome. <i>Statistics in Medicine</i> , <b>2020</b> , 39, 4016-4024	2.3
2	Cost-efficient clinical studies with continuous time survival outcomes. <i>Statistics in Medicine</i> , <b>2021</b> , 40, 3682-3694	2.3
1	Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> 2019;42:657-664. <i>Diabetes Care</i> , <b>2019</b> , 42, e137	14.6